02.28.20
Aragen Bioscience has appointed Steven Lang as vice president, biologics. Aragen, a wholly-owned subsidiary of GVK BIO, is a contract research organization (CRO) focused on accelerating biologics product development with an integrated offering that includes antibody discovery and humanization, stable cell line development, recombinant protein production and purification, and differentiated diseases models.
“It’s my pleasure to welcome Dr. Steven Lang to Aragen.” said Axel Schleyer, chief executive officer, Aragen Bioscience. “The addition of Dr. Lang is part of Aragen’s ongoing investment in our team, facilities and technologies. This multiyear expansion in our capabilities has included adding over 15,000 square feet of laboratory space, introducing our proprietary RapTr Cell Line Development services and adding mass spectrometry to our analytical tool set. Dr. Lang’s technical expertise in discovery and development as well as his track record in creating innovative and dynamic teams will be invaluable in building on Aragen’s growth.”
Prior to joining Aragen, Dr. Lang was with Genentech’s cell culture department as a director overseeing research material generation, cell line development, automation, and CHO process development covering activities from DNA to Phase 2 clinical supplies. In addition to his functional role, he led an initiative to modernize the CMC scientific data management processes. This work spawned numerous digitization efforts across the global Roche Technical Development network to drive efficiency, transparency and compliance. He also acted as a CMC leader for a project team delivering an innovative bispecific antibody into clinical trials.
“It’s my pleasure to welcome Dr. Steven Lang to Aragen.” said Axel Schleyer, chief executive officer, Aragen Bioscience. “The addition of Dr. Lang is part of Aragen’s ongoing investment in our team, facilities and technologies. This multiyear expansion in our capabilities has included adding over 15,000 square feet of laboratory space, introducing our proprietary RapTr Cell Line Development services and adding mass spectrometry to our analytical tool set. Dr. Lang’s technical expertise in discovery and development as well as his track record in creating innovative and dynamic teams will be invaluable in building on Aragen’s growth.”
Prior to joining Aragen, Dr. Lang was with Genentech’s cell culture department as a director overseeing research material generation, cell line development, automation, and CHO process development covering activities from DNA to Phase 2 clinical supplies. In addition to his functional role, he led an initiative to modernize the CMC scientific data management processes. This work spawned numerous digitization efforts across the global Roche Technical Development network to drive efficiency, transparency and compliance. He also acted as a CMC leader for a project team delivering an innovative bispecific antibody into clinical trials.
